Countdown to Partnering - John Carroll, Editor of Fierce Biotech
John Carroll, editor of Fierce Biotech, shares what he won't miss at the 2011 BIO International Convention.
TOP TEN 'CAN'T MISS' BREAKOUT SESSIONS
201 - FDA – TOWNHALL (Achieving Regulatory Approval and Compliance)
Wednesday
2:00 pm - 3:30 pm
- Outline key FDA organizational and policy initiatives.
- Present FDA's views on critical topics such as FDAAA/PDUFA V, drug safety, transparency, and Critical Path regulatory science programs.
- Stimulate interactive discussion with respect to the initiatives and issues presented.
97 - Personalized Oncology: The Emergence of Personalized Medicine Strategies in Oncology Clinical Development and Deal Making (Diagnostics & Personalized Medicine)
Tuesday
2:00 pm - 3:30 pm
- Understand scientific and market trends toward personalized medicine in oncology.
- Understand technology challenges of translating biomarkers into clinical use.
- Understand regulatory challenges of translating biomarkers into clinical use and into the marketplace.
261 - Addressing the Major Medical Challenges of Today with Personalized Medicine: Cancer, Diabetes and Brain Injury (Diagnostics and Personalized Medicine)
Tuesday
10:00 am - 11:30 am
- Review the latest achievements in developing targeted anti-cancer vaccines. Learn the potential new approaches to diabetes diagnosis and treatment based on understanding of the genetic causes of the disease.
- Learn how the development of biomarkers for TBI can impact diagnosis, management and treatment of brain injured patients.
199 - Starting Up Biotechs in the New Normal World (Finance)
Wednesday
10:00 am – 11:30 am
- Provide CEO and VC views on how biotech venture fundraising has changed between early 2008 and 2011.
- Review non-VC funding options for start-up biotechs.
- Provide an interactive forum for entrepreneurs to ask questions.
196 - Wait, Our Model Isn't Dead! We Just Need to Evolve (Finance)
Tuesday
2:00 pm - 3:30 pm
- Describe how and why VC models have evolved.
- Offer insights on how to successfully navigate the new venture landscape.
- Explain VC valuation methods and investing models.
194 - Financing Beyond the Lead Compound: Attracting Funding for Multiproduct Platforms (Finance)
Tuesday
10:00 am - 11:30 am
- Show how to build a business plan that conveys value of the company, beyond a lead candidate.
- Describe how to create strategies that attract VC financing and capitalize on the value of product.
- Showcase the potential of the value proposition for the platform and company.
199 - Starting Up Biotechs in the New Normal World (Finance)
Wednesday
10:00 am – 11:30 am
- Provide CEO and VC views on how biotech venture fundraising has changed between early 2008 and 2011.
- Review non-VC funding options for start-up biotechs.
- Provide an interactive forum for entrepreneurs to ask questions.
200 - Collaborations and Strategies to Crossing the Valley of Death to Fund Innovative Medicines (Finance)
Wednesday
2:00 pm - 3:30 pm
- Explore strategies to overcome the challenges and bottlenecks of drug development.
- Highlight current and future projects aimed at transforming drug development.
- Discuss how unique partnerships can bring innovative medicines to patients worldwide.
95 - Innovative Collaborations: Deal Structures for Nonprofit/For-Profit Collaborations (Biotech Patenting and Tech Transfer)
Thursday, June 30, 2011
8:30 am - 9:45 am
- Describe successful industry collaborations with nonprofits and drafting those clauses in your agreement.
- Explain how collaboration terms vary when one or both of the parties is a non-U.S. entity.
- List structures and terms to avoid in the interest of a successful collaboration.
188 - The Changing BD Environment: Overcoming Our Past to Succeed in the Future (Business Development)
Tuesday
2:00 pm - 3:30 pm
- Explain the dynamics (type, economics, timing, roles) driving biotech/pharma collaborations.
- Conceptualize novel approaches to biotech and pharma collaborations.
- Identify key deal showstoppers from either a historical or novel transaction approach.